Sevuparin - Modus Therapeutics/Mahidol Oxford Tropical Research Unit

Drug Profile

Sevuparin - Modus Therapeutics/Mahidol Oxford Tropical Research Unit

Alternative Names: DF-02; LAH - Modus Therapeutics; Low anticoagulant heparin - Modus Therapeutics; Sevuparin

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dilafor
  • Developer Arabian Gulf University; Mahidol Oxford Tropical Medicine Research Unit; Modus Therapeutics
  • Class Anticoagulants; Antimalarials; Antithrombotics; Heparins; Low molecular weight heparins
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Sickle cell anaemia

Most Recent Events

  • 20 Dec 2017 Updated pharmacodynamics data from a phase I/II trial in Falciparum malaria released by Modus Therapeutics
  • 22 Feb 2017 Modus Therapeutics plans clinical trials for Sickle cell anaemia (Modus Therapeutics pipeline, February 2017)
  • 03 Dec 2016 Pharmacodynamics data from a phase II trial in Sickle cell anaemia (In adolescents, In adults) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top